Occurrence of post-injection delirium/sedation syndrome after application of olanzapine long-acting injection during one year period.
Psychiatr Danub
; 29(4): 497-499, 2017 Dec.
Article
en En
| MEDLINE
| ID: mdl-29197208
ABSTRACT
INTRODUCTION:
The aim was to report the occurrence of after application of olanzapine long-acting injection (OLAI) in patients with schizophrenia during one year period. SUBJECTS ANDMETHODS:
During one year period, OLAI was applied to 30 patients with schizophrenia (18 men, 12 women) who were non-adherent to previous treatment with oral olanzapine. Patients were 20-58 years of age (39 years old on average), diagnosed with SCID based on DSM-IV-TR criteria. Patients received OLAI in dosage between 210-405 mg (287±62 (mean ± SD)) every 2-4 weeks.RESULTS:
Out of 30 patients that received OLAI, 29 patients improved significantly without side-effects, and one patient developed post-injection delirium/sedation syndrome (PDSS). The patient's somatic condition stabilized and treatment with OLAI was discontinued due to the PDSS.CONCLUSION:
The occurrence of PDSS is not common and when it occurs, in our experience, it was reversible.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Nivel de Alerta
/
Esquizofrenia
/
Psicología del Esquizofrénico
/
Benzodiazepinas
/
Trastornos de la Conciencia
/
Delirio
Tipo de estudio:
Diagnostic_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2017
Tipo del documento:
Article